MedTrace Logo

MIRNA QUANTIFICATION IN PATIENTS WITH SEPTIC SHOCK

NCT07597122 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 56

Last updated 2026-05-22

No results posted yet for this study

Summary

Sepsis-induced immunosuppression (SIS) is a common complication in patients with septic shock. Reduced expression of Human leukocyte antigen isotype DR (HLA-DR) on circulating monocytes is a marker for SIS and correlates with risk of secondary infections and mortality. The miRSep study aims to improve the understanding of early microRNA (miRNA) mediated changes in HLA-DR on monocytes in patients with septic shock.

Conditions

  • Sepsis and Septic Shock

Sponsors & Collaborators

  • Insel Gruppe AG, University Hospital Bern

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-01
Primary Completion
2027-05-31
Completion
2027-12-31

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07597122 on ClinicalTrials.gov